ImmunityBio_COVID-19_vaccine

ImmunityBio COVID-19 vaccine

ImmunityBio COVID-19 vaccine

Viral vector COVID-19 vaccine

The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector[1] COVID-19 vaccine developed by the United States-based pharmaceutical company ImmunityBio.[2][1]

Quick Facts Vaccine description, Target ...

Manufacturing

The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus vaccines. The contract with American based ImmunityBio Inc is currently conducting phase 1 vaccine trials in South Africa[3]

ImmunityBio and BioVac plan to distribute the vaccines throughout South Africa and Africa.[4][5]

History

In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.[6]

On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund monkey trials.[7] The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."[7]

Clinical trials

ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa.[3][8][9][needs update]

References

  1. [1]
    "ImmunityBio Inc: hAd5-Covid-19 – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 23 March 2021.
  2. [2]
    "SA's Biovac to team up with US based ImmunityBio in making its vaccine". BusinessInsider. Retrieved 23 March 2021.
  3. [3]
    "Covid-19 to Serve as Platform for South African Vaccine Industry". Bloomberg.com. 19 March 2021. Retrieved 20 March 2021.
  4. [4]
    Fisher S. "Nzimande excited about vaccine partnership between Biovac & ImmunityBio". ewn.co.za. Retrieved 20 March 2021.
  5. [5]
    Sguazzin A. "SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says". Fin24. Retrieved 20 March 2021.
  6. [6]
    Cross R (12 May 2020). "Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?". Chemical & Engineering News. 98 (19).
  7. [7]
    Cohen J (1 June 2020). "Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests". American Association for the Advancement of Science. Science (magazine).
  8. [8]
    "ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread". www.businesswire.com. 19 January 2021. Retrieved 23 March 2021.
  9. [9]
    Sguazzin A. "SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says". Fin24. Retrieved 23 March 2021.
Scholia has a profile for ImmunityBio COVID-19 vaccine (Q106616925).
Share this article:

This article uses material from the Wikipedia article ImmunityBio_COVID-19_vaccine, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.